IRadimed Corporation (IRMD) Cash Flow Statement

The OCF/NI ratio dipped below 1.0 in 2025Q1 and 2025Q4, but recovered to 1.14 in 2026Q2, suggesting that the EPS miss was not driven by deteriorating cash generation. The consistent excess of operating cash flow over net income, even during the 3870 launch, implies that accruals are not inflating earnings, and the quality of earnings appears robust.

The FCF margin volatility in 2025Q1 (3.0%) and 2025Q2 (24.1%) reflects elevated capex during the 3870 launch, but the subsequent quarters show a return to the mid-to-high 20s range. This suggests that the launch-related capital intensity was temporary, and the underlying business continues to convert revenue into cash at a healthy rate, though investors should monitor whether the new platform sustains this trajectory.

The elevated capex in 2024-2025 aligns with the preparation for the 3870 pump launch, likely including tooling and production line investments. The sharp decline in 2026Q2 suggests that the heavy investment phase is complete, and the company is now operating with minimal capital requirements, which supports high FCF conversion. However, the low capex/revenue ratio also implies that future growth may not require significant capital, but any new product development could reverse this trend.

The negative working capital change in 2025Q4 suggests a build-up of inventory or receivables ahead of the 3870 launch, while the positive change in 2026Q1 indicates a release of cash as those assets were converted. The modest -$344K change in 2026Q2 suggests stabilization, but the volatility in working capital is a reminder that quarterly cash flows can be lumpy during product transitions. Investors should focus on the longer-term trend, which appears manageable.

The company's capital deployment is conservative, with dividends being the primary use of cash, and no share repurchases or M&A activity. The dividend payout ratio, while not excessive, leaves limited room for organic reinvestment beyond the low capex requirements. This suggests a mature, cash-return-focused approach, but also implies that management may be accumulating cash for future opportunities or as a buffer, given the $51M+ cash balance.

The cumulative excess of operating cash flow over net income by $12.1M suggests that earnings are backed by real cash generation, with non-cash charges like D&A and SBC adding back, while working capital changes have been modest. This divergence is a positive signal for earnings quality, but investors should note that the gap could narrow if working capital needs increase with the 3870 ramp. The consistency of this trend supports the view that IRMD's profitability is not merely an accounting artifact.